Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy

Gentilly,,France,,March,21,,2021:,Sign,And,Logo,On,The

Sanofi SA (NASDAQ:SNY) on Wednesday revealed topline data from the ElevAATe phase 2 study of efdoralprin alfa (SAR447537, formerly known as INBRX-101), for alpha-1 antitrypsin deficiency (AATD) emphysema.

AATD causes emphysema when the body doesn’t produce enough of the protective alpha-1 antitrypsin (AAT) protein, leading to a breakdown of the lung’s air sacs (alveoli).

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.